Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Assets (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Current Assets for 16 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 105.84% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, up 105.84%, and an annual FY2025 reading of $950.6 million, up 36.69% over the prior year.
  • Current Assets was $1.2 billion for Q4 2025 at Arrowhead Pharmaceuticals, up from $950.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.2 billion in Q4 2025 and bottomed at $237.9 million in Q4 2023.
  • Average Current Assets over 5 years is $591.5 million, with a median of $533.8 million recorded in 2021.
  • The sharpest move saw Current Assets plummeted 58.63% in 2023, then surged 139.82% in 2024.
  • Year by year, Current Assets stood at $338.3 million in 2021, then skyrocketed by 69.98% to $575.0 million in 2022, then tumbled by 58.63% to $237.9 million in 2023, then surged by 139.82% to $570.5 million in 2024, then surged by 105.84% to $1.2 billion in 2025.
  • Business Quant data shows Current Assets for ARWR at $1.2 billion in Q4 2025, $950.6 million in Q3 2025, and $946.9 million in Q2 2025.